. 2015 Oct 19;2015:416838. doi: 10.1155/2015/416838

Table 6.

Evaluation of a genetic test for response to IFX after 1 year of treatment of the CD patients with both concomitant use of immunomodulators and penetrating disease.

Factor	Number of CD patients (%)		OR (95% CI)	P value^∗
	Responders	Nonresponders
	n = 4	n = 5
Both G/G genotype of rs766748 in IL17F and C/C and C/A genotype of rs1883136 in TRAF3IP2	4 (100)	0 (0)	99.00 (1.618–6059)	0.0079
Others	0 (0)	5 (100)	99.00 (1.618–6059)	0.0079

^∗Factors were statistically analyzed by Fisher's exact test.

IFX: infliximab; CD: Crohn's disease; OR: odds ratio; CI: confidence interval.